Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Portfolio Pulse from Vandana Singh
Equillium Inc. (NASDAQ:EQ) announced topline data from its Phase 2 study of EQ101 for alopecia areata, showing favorable safety and tolerability but mixed efficacy results. EQ shares fell 21.8% following the announcement.
June 04, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Equillium Inc. (NASDAQ:EQ) reported mixed results from its Phase 2 study of EQ101 for alopecia areata. While the safety profile was favorable, the efficacy results were less impressive, leading to a 21.8% drop in share price.
The mixed results from the Phase 2 study, particularly the less impressive efficacy data, have led to a significant drop in Equillium's share price. Investors are likely concerned about the drug's potential market success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100